Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada

Canadian Journal of Public Health

Volumn 97, Issue 3, 2006, Pages 171-176

  Beaulac, Jennifer A ^a   Fry, Richard N ^a   Onysko, Jay ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Cross sectional studies; Mass screening; Practice guidelines; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CALCULATION; CANADA; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; ETHNOLOGY; GENERAL PRACTITIONER; HEALTH BEHAVIOR; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; LANGUAGE; LIFESPAN; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PROSTATE CANCER; PUBLIC HEALTH; SELF REPORT;

EID: 33745889588     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405578     Document Type: Article

References (43)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto, ON, 2006.
2. Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997;47:273-87.
3. Moul JW. Screening for prostate cancer in African Americans. Current Urology Reports 2000;1:57-64.
4. Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, et al. Targeted screening for prostate cancer in high risk families: Early onset is a significant risk factor for disease in first degree relatives. J Urology 2002;168(2):483-87.
5. Krahn MD, Coombs BA, Levy IG. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen. CMAJ 1998;160:49-57.
6. Turini M, Redaelli A, Gramegna P, Radice D. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 2003;21(8):527-41.
7. Woolf SH. The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound. A review of published scientific evidence. Int J Technology Assessment in Health Care 2001;17(3):275-304.
8. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-42.
9. de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: Program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002;97(2):237-44.
10. Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK; PLCO Steering Committee. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. Urol Oncol 2004;22(4):358-61.
11. Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 2004;10(7):2231-36.
12. Feightner JW. Screening for prostate cancer. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa, ON: Health Canada, 1994;812-23.
13. Ferrini R, Woolf SH. Screening for prostate cancer in American men. American College of Preventive Medicine Practice Policy Statement. Available online at: http://www.acpm.org/prostate.html (Accessed September 28, 2004).
14. National Health Service. Prostate Cancer Risk Management Programme. 2001 Available online at: http://www.cancerscreening.nhs.uk/prostate/index.html (Accessed September 28, 2004).
15. Second Report of the UK National Screening Committee. 2000. Available online at: http://www.nsc.nhs.uk/pdfs/secondreport.pdf (Accessed September 28, 2004).
16. British Association of Urological Surgeons. Guidelines on the management of prostate cancer. 1999. Available online at: http://www.nelh.uk/guidelinesdb/html/Prostate-ft.html (Accessed September 28, 2004).
17. Australian Government Department of Health and Aging. Prostate cancer screening - Summary of the review prepared by the Australian Health Technology Advisory Committee, 1996. Available online at: http://www.health.gov.au/pubs/ahtac/prostate.html (Accessed September 28, 2004).
18. National Advisory Committee on Health and Disability (National Health Committee) (New Zealand). Prostate cancer screening in New Zealand. Report to the Minister of Health. Wellington: 2004. Available online at: http://www.nhc.govt.nz (Accessed September 28, 2004).
19. American Urological Association. AUA supports prostate-specific antigen testing. Press Releases. Available online at: http://www.auanet.org/press/releases/antigentesting.cfm (Accessed September 28, 2004).
20. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, et al. American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers. CA Cancer J Clin 2001;51:38-75.
21. Urological Society of Australia. PSA Screening for Prostate Cancer. 1999. Available online at: http://www.urosoc.org.au/info/ainfo.html (Accessed September 28, 2004).
22. Ramsey EW. Early detection of prostate cancer. Recommendations from the Canadian Urological Association. Can J Oncol 1994;4(Suppl 1):82-85.
23. BC Cancer Agency. Evaluation of screening for prostate cancer with PSA. 2001. Available online at: http://www.bccancer.bc.ca/pg_g_04.asp?PageID=2742&ParentID=4 (Accessed September 28, 2004).
24. U.S. Preventive Services Task Force. Screening for prostate cancer: Recommendation and rationale. Ann Intern Med 2002;137(11):915-16.
25. Canadian Cancer Society. Available online at: http://www.cancer.ca (Accessed September 28, 2004).
26. Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemoprevention. Am J Prev Med 2004;26(1):56-66.
27. Bunting PS, Goel V, Williams JI, Iscoe NA. Prostate-specific antigen testing in Ontario: Reasons for testing patients without diagnosed prostate cancer. CMAJ 1999;160(1):70-75.
28. McGregor SE, Bryant HE, Brant RF, Corbett PJ. Prevalence of PSA testing and effect of clinical indications on patterns of PSA testing in a population-based sample of Alberta men. Chron Dis Can 2002;23(3):111-19.
29. Gibbons L, Waters C. Prostate cancer - testing, incidence, surgery and mortality. Health Rep 2003;14(3):9-20.
30. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States. Does practice reflect the evidence? JAMA 2003;289(11):1414-20.
31. Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O'Reilly D, et al. Evidence of prostate cancer screening in a UK region. BJU International 2004;93:730-34.
32. Béland Y. Canadian community health survey - methodological overview. Health Rep 2002;13(3):9-14.
33. Yeo D, Mantel H, Tzen-Ping L. Bootstrap variance estimation for the national population health survey. Proceedings of the Survey Research Methods Section, American Statistical Association. 1999;778-83. Available online at: http://www.amstat.org/sections/srms/Proceedings (Accessed September 28, 2004).
34. Robbins AS, Chao SY, Fonseca VP. What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes. Ann Epidemiol 2002;12:452-54.
35. Tudiver F, Guibert R, Haggerty J, Ciampi A, Medved W, Brown JB, et al. What influences family physicians' cancer screening decisions when practice guidelines are unclear or conflicting? J Fam Pract 2002;51(9):760.
36. Mercer SL, Goel V, Levy IG, Ashbury FD, Iverson DC, Iscoe NA. Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions. Can J Public Health 1997;88(5):327-32.
37. Bunting PS. Laboratory survey of prostate-specific antigen testing in Ontario updated. Clin Biochemistsy 2004;37:418-21.
38. Plaskon L, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol, Biomarkers Prev 2003;12:604-9.
39. Guibert R, Leduc N, Fournier P, Tetreault H. What factors determine whether individuals found to have hypercholesterolaemia at mass screening accept advice to visit their physician. Public Health 1999;113(3):105-10.
40. Dyer PH, Lloyd CE, Lancashire RJ, Bain SC, Barnett AH. Factors associated with clinic non-attendance in adults with type 1 diabetes mellitus. Diabet Med 1998;15(4):339-43.
41. Preisser JS, Cohen SJ, Wofford JL, Moran WP, Shelton BJ, McClatchey MW, Wolfe P. Physician and patient predictors of health maintenance visits. Arch Fam Med 1998;7(4):346-51.
42. Hall HI, Van Den Eeden SK, Tolsma DD, Rardin K, Thompson T, Hughes Sinclair A, et al. Testing for prostate and colorectal cancer: Comparison of self-report and medical record audit. Prev Med 2004;39:27-35.
43. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Reports 2004;119(2):174-86.